Chuangsheng Group, formerly known as Mai Bo Si Bio, launched the plan to merge with the biopharmaceutical company Ian Jishi on 20 17. Chuangsheng Group was merged by Mai Bo Si Bio and Yi 'an Jishi Bio-pharmaceutical in 20 19, with a valuation of about 65438+88 million USD.
Chuangsheng Group has established an excellent team with rich international experience. The R&D pipeline will be expanded to more than 65,438+00 new drug molecules, covering tumor, osteopathy, nephropathy and other fields. Hangzhou Technology and Production Center adopts continuous casting production technology. And reached an exclusive import agreement with Lilly Pharmaceutical, and obtained the authorization of its whole product line of osteopathic innovative biopharmaceuticals (including Blosozumab which has completed the second phase clinical trial) in Greater China.